Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

Trial Profile

Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Pazopanib (Primary) ; Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms SUP-R
  • Most Recent Events

    • 07 Aug 2017 Planned End Date changed from 1 Apr 2020 to 1 Jun 2021.
    • 07 Aug 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jun 2021.
    • 01 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top